Cutter Capital Management LP Acquires 115,000 Shares of Agios Pharmaceuticals, Inc. (NASDAQ:AGIO)

Cutter Capital Management LP increased its position in shares of Agios Pharmaceuticals, Inc. (NASDAQ:AGIO - Free Report) by 61.6% during the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The firm owned 301,623 shares of the biopharmaceutical company's stock after purchasing an additional 115,000 shares during the period. Agios Pharmaceuticals comprises about 4.1% of Cutter Capital Management LP's investment portfolio, making the stock its 12th largest position. Cutter Capital Management LP owned about 0.53% of Agios Pharmaceuticals worth $9,911,000 at the end of the most recent reporting period.

A number of other hedge funds also recently made changes to their positions in AGIO. Vanguard Group Inc. raised its stake in shares of Agios Pharmaceuticals by 1.5% in the fourth quarter. Vanguard Group Inc. now owns 5,631,321 shares of the biopharmaceutical company's stock worth $185,045,000 after acquiring an additional 85,339 shares during the last quarter. Fisher Asset Management LLC raised its holdings in Agios Pharmaceuticals by 12.3% during the 4th quarter. Fisher Asset Management LLC now owns 960,661 shares of the biopharmaceutical company's stock worth $31,567,000 after buying an additional 105,333 shares during the period. ArrowMark Colorado Holdings LLC boosted its stake in Agios Pharmaceuticals by 3.9% in the 4th quarter. ArrowMark Colorado Holdings LLC now owns 917,420 shares of the biopharmaceutical company's stock worth $30,146,000 after purchasing an additional 34,689 shares during the period. Caligan Partners LP grew its holdings in shares of Agios Pharmaceuticals by 8.0% during the fourth quarter. Caligan Partners LP now owns 626,280 shares of the biopharmaceutical company's stock worth $20,580,000 after buying an additional 46,563 shares in the last quarter. Finally, Northern Trust Corp boosted its holdings in Agios Pharmaceuticals by 0.9% during the fourth quarter. Northern Trust Corp now owns 595,480 shares of the biopharmaceutical company's stock worth $19,567,000 after purchasing an additional 5,372 shares during the last quarter.

Agios Pharmaceuticals Trading Down 2.6 %

AGIO traded down $0.72 on Friday, reaching $27.32. The stock had a trading volume of 303,182 shares, compared to its average volume of 697,008. The company has a market capitalization of $1.58 billion, a price-to-earnings ratio of 2.41 and a beta of 0.77. The firm has a 50-day moving average of $29.23 and a 200-day moving average of $37.22. Agios Pharmaceuticals, Inc. has a fifty-two week low of $23.42 and a fifty-two week high of $62.58.

Agios Pharmaceuticals (NASDAQ:AGIO - Get Free Report) last released its quarterly earnings results on Thursday, May 1st. The biopharmaceutical company reported ($1.55) EPS for the quarter, beating analysts' consensus estimates of ($1.80) by $0.25. Agios Pharmaceuticals had a negative return on equity of 2.51% and a net margin of 1,845.92%. The firm had revenue of $8.73 million for the quarter, compared to analyst estimates of $9.86 million. Sell-side analysts anticipate that Agios Pharmaceuticals, Inc. will post -6.85 EPS for the current fiscal year.

Wall Street Analysts Forecast Growth

AGIO has been the topic of a number of analyst reports. StockNews.com upgraded Agios Pharmaceuticals from a "sell" rating to a "hold" rating in a research note on Saturday. Scotiabank reduced their target price on shares of Agios Pharmaceuticals from $74.00 to $71.00 and set a "sector outperform" rating for the company in a research report on Friday, May 2nd. Finally, HC Wainwright assumed coverage on Agios Pharmaceuticals in a research report on Monday, February 24th. They set a "buy" rating and a $58.00 target price for the company. Five investment analysts have rated the stock with a hold rating and five have issued a buy rating to the company. Based on data from MarketBeat, the company presently has a consensus rating of "Moderate Buy" and a consensus target price of $56.00.

Insider Transactions at Agios Pharmaceuticals

In other news, Director Jacqualyn A. Fouse sold 7,497 shares of the stock in a transaction dated Thursday, April 10th. The shares were sold at an average price of $25.90, for a total transaction of $194,172.30. Following the transaction, the director now owns 149,220 shares of the company's stock, valued at $3,864,798. This represents a 4.78 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Corporate insiders own 4.93% of the company's stock.

Agios Pharmaceuticals Profile

Agios Pharmaceuticals, Inc, a biopharmaceutical company, discovers and develops medicines in the field of cellular metabolism in the United States. Its lead product includes PYRUKYND (mitapivat), an activator of wild-type and mutant pyruvate kinase (PK), enzymes for the treatment of hemolytic anemias.